NEW ORLEANS — Consolidation therapy with high-dose chemotherapy followed by hematopoietic stem cell transplant significantly prolonged PFS among adults with primary central nervous system lymphoma, according to study results.
Data from the randomized phase 3 MATRix/IELSG43 trial — presented at ASH Annual Meeting and Exposition — showed the combination also significantly extended OS when compared with a standard regimen of nonmyeloablative immunochemotherapy, researchers noted.
Treatment of primary CNS lymphoma is particularly challenging due to its aggressive nature and